Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge

查看全文 作　　者：Qianyun [1,2]Liu;Haiyan [1]Zhao;Zhiqiang [3]Li;Zhen [4]Zhang;Rui [5]Huang;Mengxue [1]Gu;Ke [4]Zhuang;Qing [1]Xiong;Xianying [1]Chen;Weiyi [1]Yu;Shengnan [1]Qian;Yuzhen [1]Zhang;Xue [1]Tan;Muyi [5]Zhang;Feiyang [1]Yu;Ming [1]Guo;Zhixiang [4]Huang;Xin [1]Wang;Wenjie [1]Xiang;Bihao [3]Wu;Fanghua [6]Mei;Kun [6]Cai;Limin [7]Zhou;Li [4]Zhou;Ying [5]Wu;Huan [1]Yan;heng [3]Cao;Ke [1]Lan;Yu [1,2]Chen 机构地区：[1]State Key Laboratory of Virology,Instute for Vaccine Research,College of Life Sciences,Wuhan University,Wuhan 430072,China;[2]Department of Thoracic Surgery,Renmin Hospital,Wuhan University,Wuhan,China;[3]CAS Key Laboratory of Special Pathogens,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan 430o71,P.R.China;[4]Animal Biosafety Level-ll Laboratory/lnstitute for Vaccine Research,Wuhan University,Wuhan,China;[5]State Key Laboratory of Virology and Hubei Province Key Laboratory of Allergy and Immunology,Institute of Medical Virology,Taikang Medical School,Wuhan University,Wuhan 430072,China;[6]Hubei Center for Disease Control and Prevention,Wuhan 430079,China;[7]Maternal and Child Health Hospital of Hubei Province,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China 出　　处：《Signal Transduction and Targeted Therapy》索引2023年第8卷第10期,共13页 基　　金：This study was supported by the National Natural Science Foundation of China(32188101 to K.L.,32122008 to Y.W.,32270164 to H.Y.,and 32070160 to H.Y.);National Science and Technology Major Project(2022YFC2604100 to H.Z.and L.Z.,2021YFC2300702 to L.Z.,and 2021YFF0702004 to Y.C.);Fundamental Research Funds for the Central Universities(2042023kf0191 and 2042022kf1188 to H.Y.);Hubei Provincial Natural Science Foundation(2023AFA015 to H.Y.),China Postdoctoral Science Foundation(2023M732705 to Q.L.);Hubei Provincial Public Health Outstanding Young Talents Project(to K.C.). 摘　　要：Coronavirus disease 2019(COviD-19)was first reported three years ago,when a group of individuals were infected with the original SARS-CoV-2 strain,based on which vaccines were developed.Here,we develop six human monoclonal antibodies(mAbs)from two elite convalescents in Wuhan and show that these mAbs recognize diverse epitopes on the receptor binding domain(RBD)and can inhibit the infection of SARS-CoV-2 original strain and variants of concern(VOCs)to varying degrees,including Omicron strains XBB and XBB. 关 键 词：antibodies MONOCLONAL neutral